Loading...
•
Mar 31
PetMed Express Q4 2025 Earnings Report
Expected Revenue:$50M
-22.4% YoY
Expected EPS:-$0.06
+16.4% YoY
Key Takeaways
PetMed Express experienced a challenging fourth quarter in fiscal year 2025, with estimated net sales decreasing to a range of $51.1 million to $53.1 million from $66.5 million in the prior year, and an estimated net loss widening to $9.9 million to $10.4 million from $5.0 million. The net loss for the quarter included a significant $6.4 million tax expense impact from a valuation allowance on deferred tax assets. For the full fiscal year, net sales are estimated to be between $231.6 million and $233.6 million, down from $281.1 million, and the net loss is estimated to be $4.5 million to $5.0 million, an improvement from a $7.5 million net loss in the prior year, partly due to a one-time stock compensation reversal.
Q4 2025 net sales are estimated to be between $51.1 million and $53.1 million, a significant decrease from $66.5 million in Q4 2024.
Q4 2025 net loss is estimated to range from $9.9 million to $10.4 million, compared to a net loss of $5.0 million in the prior year period.
The Q4 2025 net loss includes a $6.4 million tax expense impact due to a valuation allowance on net deferred tax assets.
As of March 31, 2025, the company reported $54.7 million in cash and no debt.
PetMed Express
PetMed Express
Forward Guidance
PetMed Express expects to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, by July 1, 2025. The company will reschedule its earnings release and conference call once the filing date is confirmed. The preliminary financial information is subject to change based on final adjustments and audit developments.
Positive Outlook
- The company expects to file its Annual Report on Form 10-K by July 1, 2025.
- The company had $54.7 million of cash and no debt as of March 31, 2025.
- The full fiscal year 2025 net loss is estimated to be an improvement compared to the prior year.
- The company is a pioneer in direct-to-consumer pet healthcare.
- PetMeds is licensed across all 50 states with expert pharmacists.
Challenges Ahead
- The company was unable to file its Annual Report on Form 10-K within the prescribed time period.
- Preliminary Q4 2025 net sales are significantly lower than the prior year period.
- Preliminary Q4 2025 net loss is higher than the prior year period.
- The Q4 2025 net loss includes a $6.4 million tax expense impact from a valuation allowance on deferred tax assets.
- The estimated financial information is preliminary and unaudited, subject to change.
Loading...
Key Statistics
Market Cap
$66.9M
P/E Ratio
308.27
Sector
Retail Trade
Industry
Specialty Stores
52-Week High
$6.58
52-Week Low
$2.94